{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+4&page=71",
    "query": {
      "intervention": "cohort 4",
      "page": 71
    },
    "page_size": 10
  },
  "pagination": {
    "page": 71,
    "page_size": 10,
    "total_count": 3785,
    "total_pages": 379,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+4&page=72&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cohort+4&page=70&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-21T17:50:13.255Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02846142",
      "title": "Study to Assess the Safety, Tolerability, PK, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "PTI-428",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "ethinyl estradiol and levonorgestrel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Proteostasis Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 55 Years · Female only"
      },
      "enrollment_count": 94,
      "start_date": "2016-06",
      "completion_date": "2017-03",
      "has_results": false,
      "last_update_posted_date": "2018-05-24",
      "last_synced_at": "2026-11-21T17:50:13.255Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02846142"
    },
    {
      "nct_id": "NCT02481297",
      "title": "Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Chronic Lymphocytic Leukemia",
        "Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Lirilumab",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2015-06-23",
      "completion_date": "2019-08-15",
      "has_results": true,
      "last_update_posted_date": "2020-05-28",
      "last_synced_at": "2026-11-21T17:50:13.255Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02481297"
    },
    {
      "nct_id": "NCT02938013",
      "title": "deLIVER: Direct Acting Antiviral Effects on the Liver",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HCV Coinfection",
        "Liver Disease",
        "HIV"
      ],
      "interventions": [
        {
          "name": "Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX]",
          "type": "DRUG"
        },
        {
          "name": "Sofosbuvir/Velpatasvir (SOF/VEL)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 15,
      "start_date": "2017-01",
      "completion_date": "2020-09-30",
      "has_results": true,
      "last_update_posted_date": "2022-02-24",
      "last_synced_at": "2026-11-21T17:50:13.255Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02938013"
    },
    {
      "nct_id": "NCT05364073",
      "title": "Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer (NSCLC)",
        "Metastatic Non-Small Cell Lung Cancer",
        "Advanced Non-Small Cell Lung Cancer",
        "HER2 Exon 20 Mutations",
        "EGFR Exon 20 Mutations",
        "EGFR Uncommon Mutations, Including G719X and S768I"
      ],
      "interventions": [
        {
          "name": "Furmonertinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ArriVent BioPharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 160,
      "start_date": "2022-06-30",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-11-12",
      "last_synced_at": "2026-11-21T17:50:13.255Z",
      "location_count": 7,
      "location_summary": "Prescott, Arizona • Sacramento, California • Whittier, California + 4 more",
      "locations": [
        {
          "city": "Prescott",
          "state": "Arizona"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Celebration",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05364073"
    },
    {
      "nct_id": "NCT04934124",
      "title": "Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITI 333 in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "ITI-333",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Intra-Cellular Therapies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 48,
      "start_date": "2020-12-23",
      "completion_date": "2021-08-23",
      "has_results": false,
      "last_update_posted_date": "2023-03-14",
      "last_synced_at": "2026-11-21T17:50:13.255Z",
      "location_count": 1,
      "location_summary": "Eatontown, New Jersey",
      "locations": [
        {
          "city": "Eatontown",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04934124"
    },
    {
      "nct_id": "NCT07504796",
      "title": "ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Melanoma",
        "Advanced Melanoma"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Relatlimab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Signatera genome MRD assay",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2026-04-13",
      "completion_date": "2031-05",
      "has_results": false,
      "last_update_posted_date": "2026-08-24",
      "last_synced_at": "2026-11-21T17:50:13.255Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07504796"
    },
    {
      "nct_id": "NCT01925261",
      "title": "A Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 in Subjects With Mild to Moderate Patello-Femoral Osteoarthritis Involving Both Knees",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Knee Osteoarthritis"
      ],
      "interventions": [
        {
          "name": "TPX-100 50mg",
          "type": "DRUG"
        },
        {
          "name": "TPX-100 100mg",
          "type": "DRUG"
        },
        {
          "name": "TPX-100 200mg",
          "type": "DRUG"
        },
        {
          "name": "TPX-100 20mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OrthoTrophix, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "25 Years to 75 Years"
      },
      "enrollment_count": 120,
      "start_date": "2014-01",
      "completion_date": "2016-09",
      "has_results": false,
      "last_update_posted_date": "2017-04-21",
      "last_synced_at": "2026-11-21T17:50:13.255Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01925261"
    },
    {
      "nct_id": "NCT03214666",
      "title": "GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "High-risk Myelodysplastic Syndromes",
        "Acute Myelogenous Leukemia",
        "Systemic Mastocytosis",
        "Mast Cell Leukemia"
      ],
      "interventions": [
        {
          "name": "GTB-3550 TriKE® Phase I",
          "type": "DRUG"
        },
        {
          "name": "GTB-3550 TriKE® Phase II",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GT Biopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2020-01-01",
      "completion_date": "2021-09-29",
      "has_results": true,
      "last_update_posted_date": "2022-11-10",
      "last_synced_at": "2026-11-21T17:50:13.255Z",
      "location_count": 2,
      "location_summary": "Minneapolis, Minnesota • Madison, Wisconsin",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03214666"
    },
    {
      "nct_id": "NCT02959827",
      "title": "Iodinated Contrast Agents and Risk of Hypothyroidism in Young Children in the United States",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hypothyroidism"
      ],
      "interventions": [
        {
          "name": "Iodinated contrast agents",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "3 Years",
        "sex": "ALL",
        "summary": "Up to 3 Years"
      },
      "enrollment_count": 2320,
      "start_date": "2016-10-15",
      "completion_date": "2017-06-15",
      "has_results": true,
      "last_update_posted_date": "2019-01-30",
      "last_synced_at": "2026-11-21T17:50:13.255Z",
      "location_count": 1,
      "location_summary": "Oakland, California",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02959827"
    },
    {
      "nct_id": "NCT02816346",
      "title": "Dose-Finding Study of Lyophilized Shigella Sonnei 53G Challenge Strain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Shigella sonnei 53G",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "PATH",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 56,
      "start_date": "2016-09-12",
      "completion_date": "2017-12-31",
      "has_results": true,
      "last_update_posted_date": "2019-06-03",
      "last_synced_at": "2026-11-21T17:50:13.255Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02816346"
    }
  ]
}